Qualia Clinical Services and Tandem Labs have entered a strategic alliance in an effort to create a value proposition for the pharma, biopharma and generic industries by providing access to streamlined drug development services with an emphasis on quality and efficiency.
The two companies will offer clients access to the complete suite of services related to clinical research. Through the alliance, clients can expect synchronized scheduling to minimize “downtime” between clinical completion and sample transfer for bioanalysis, utilize the companies as one resource, and maintain a single point of contact throughout all aspects of the project, according to the companies.
“The need for accurate data delivered in a timely fashion is critical to our clients. Through our alliance with Tandem Labs, Qualia now has access to one of the leading bioanalytical laboratories. Their core values are aligned with ours—both companies are client focused and have a passion for quality. The foundation of combined industry experience is quite impressive,” said Sohail Khattak, M.D., FRCP(C), president and chief executive officer, Qualia.
“This alliance gives us the unique opportunity to partner with another CRO that provides exceptional customer care combined with scientific expertise,” said Denis Lin, Ph.D., president and chief executive officer, Tandem Labs. “It is a true partnership: Qualia’s strong clinical research foundation combined with Tandem’s scientific knowledge, low-risk approach, and technologies.”